Conversation with The Cancer Letter Hyman: “This approval adds to the growing utility of sequencing in patients with cancer” November 30, 2018Vol.44 No.44By Paul Goldberg
FDA approves second drug for a site-agnostic indication;larotrectinib was tested across 17 cancer types November 30, 2018Vol.44 No.44By Paul Goldberg
FreeTrials & Tribulations Deciphering genomic testing options for diverse patient populations in early-stage breast cancer November 16, 2018Vol.44 No.43By Adam Brufsky
FreeGuest Editorial Trump pricing plans are pretentious, could impede access, and will not help much November 16, 2018Vol.44 No.43By Patricia J. Goldsmith
Free Artificial intelligence can entrench disparities—here’s what we must do November 16, 2018Vol.44 No.43By Kadija Ferryman and Robert A. Winn
FreeObituary Arti Hurria, geriatric oncologist at City of Hope, dies in traffic accident November 09, 2018Vol.44 No.42By Michael Easterling
Conversation with The Cancer Letter Jaffee: Congressional commitment to NIH will continue through FY2021 November 09, 2018Vol.44 No.42By Paul Goldberg
Conversation with The Cancer Letter Brawley: “I started out talking about black-and-white disparities, and now I write papers talking about state-by-state disparities” November 09, 2018Vol.44 No.42By Paul Goldberg
